Alumni, Life Science & MedTech

MgShell

The number of people affected by maculopathy is dramatically increasing and the therapeutical adherence is so low that 40% of patients does not follow the correct strategy and goes to blindness. MgShell is developing an innovative game changer in the treatment space, an intraocular device able to release drug doses for the entire treatment, minimizing the clinical burdens. MgShell proposes the only autonomous solution able to replicate the clinical practice without surgery, doing compliance for patients, decrease of overheads for Healthcare systems, and business for companies.

The number of people affected by maculopathy is dramatically increasing and the therapeutical adherence is so low that 40% of patients does not follow the correct strategy and goes to blindness. MgShell is developing an innovative game changer in the treatment space, an intraocular device able to release drug doses for the entire treatment, minimizing the clinical burdens. MgShell proposes the only autonomous solution able to replicate the clinical practice without surgery, doing compliance for patients, decrease of overheads for Healthcare systems, and business for companies.